It can be hard to explain what a true migraine feels like. It is not simply a bad headache. It is throbbing pain that can pin a person in a darkened, silent room for hours or even days, often accompanied by nausea, visual disturbances and a sensitivity to light and sound so severe that ordinary life grinds to a halt.
Here in the Coachella Valley, where bright sun and dramatic shifts in barometric pressure are part of daily life, many of our neighbors know this experience all too well.
Migraine affects an estimated one in seven people worldwide, and for a significant number of them, it is not an occasional inconvenience, but a chronic, disabling condition that disrupts work, relationships and simple daily functioning. As a physician and researcher here in Palm Springs, I want our community to know about a clinical trial now enrolling at our clinic: a post-market approval study comparing three medications already approved and available for migraine treatment and prevention.
Unlike trials that test brand-new, not-yet-approved drugs, this study focuses on medications that have already cleared the U.S. Food and Drug Administration approval process and are currently prescribed to patients across the country. What remains less clear, and what this research aims to clarify, is how these three approved therapies actually compare to one another in real-world use: Which patients respond best to which option? How do side-effect profiles differ in practice? How does effectiveness hold up outside the more-controlled setting of the original approval trials? This kind of head-to-head, real-world comparison is the sort of information that helps family-medicine physicians like myself make better, more individualized treatment decisions for our patients long after a drug reaches the market.
Because all three medications in this study are already FDA-approved, participants are not being asked to try something unproven or experimental. Instead, participation involves being assigned to one of the three established treatments, and then being followed closely by our research team over the course of the study. Participants receive a detailed headache and symptom tracking diary, and consistent follow-up visits with a team that understands migraine deeply. Many participants find real value in this heightened level of attention and structured follow-up, on top of receiving a treatment already trusted by physicians nationwide.
I know that living with migraine can make people wary of adding anything new or uncertain into their routine, and that hesitation is completely reasonable. I encourage anyone considering this study to ask direct questions about what participation involves, how much time it requires, and what safety monitoring is in place. Every clinical trial we conduct follows rigorous protocols overseen by independent ethics boards whose job is to protect participants first. Informed consent is an ongoing conversation, not a one-time signature, and participants remain free to withdraw at any time, for any reason, without any impact on their regular medical care.
Migraine is often called an invisible illness, in part because so much of the suffering happens behind closed doors, away from public view. That invisibility can make it easy to overlook, but the toll it takes on our friends, family members and neighbors is very real. Advancing better treatments requires people willing to step forward and participate in the research that makes new therapies possible.
If migraines are limiting your life, or you know someone whose days are shaped around avoiding the next attack, I invite you to reach out to our research clinic to learn more about this study and whether you may be eligible.
Because this study compares medications already on the market used as preventative treatment, it offers a different kind of opportunity than a typical drug trial—the chance to receive an established, approved treatment while contributing to a clearer picture of how these options compare for patients like you.
Dr. Gemma Kim is the principal investigator for DPMG Clinical Research in Palm Springs. Learn more at www.dpmgcr.com.
